Capital Research Global Investors’s Madrigal Pharmaceuticals MDGL Stock Holding History

Capital Research Global Investors’s Portfolio MDGL Stock Details MDGL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-466,422	Closed	-$45.4M	–	452
2021 Q2	$45.4M	Sell	466,422 -1,426,644	-75%	-$169M	0.01%	375
2021 Q1	$221M	Buy	1,893,066 +2,279	+0.1%	+$266K	0.05%	236
2020 Q4	$210M	Buy	1,890,787 +5,460	+0.3%	+$667K	0.05%	240
2020 Q3	$224M	Buy	1,885,327 +188,208	+11%	+$20.4M	0.07%	205
2020 Q2	$192M	Hold	1,697,119	–	–	0.06%	212
2020 Q1	$113M	Hold	1,697,119	–	–	0.04%	224
2019 Q4	$155M	Buy	1,697,119 +13,850	+0.8%	+$1.34M	0.05%	227
2019 Q3	$145M	Buy	1,683,269 +7	+0%	+$657	0.05%	237
2019 Q2	$176M	Buy	1,683,262 +18,810	+1%	+$2.01M	0.06%	217
2019 Q1	$208M	Hold	1,664,452	–	–	0.07%	205
2018 Q4	$188M	Hold	1,664,452	–	–	0.07%	209
2018 Q3	$356M	Buy	1,664,452 +294,200	+21%	+$73.8M	0.1%	174
2018 Q2	$383M	Buy	1,370,252 +373,359	+37%	+$65.6M	0.1%	165
2018 Q1	$116M	Buy	+996,893	New	+$123M	0.03%	284

Other funds holding MDGL

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Capital Research Global Investors's MDGL Position: Q3 2021 in Review

Capital Research Global Investors sold out of Madrigal Pharmaceuticals (MDGL) in Q3 2021, closing a stake of 466,422 shares — an estimated $45.4M sold.

Capital Research Global Investors first reported a position in MDGL in Q1 2018 and held it in 14 quarters. The position peaked at $383M in Q2 2018. 133 funds tracked by Wall St. Rank hold MDGL as of Q3 2021.

Capital Research Global Investors reported no remaining Madrigal Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
Capital Research Global Investors sold 466,422 Madrigal Pharmaceuticals shares in Q3 2021, an estimated $45.4M.
Capital Research Global Investors first reported a position in Madrigal Pharmaceuticals in Q1 2018 and held it in 14 quarters.
Capital Research Global Investors's Madrigal Pharmaceuticals position peaked at $383M in Q2 2018.
133 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q3 2021.

Based on Capital Research Global Investors's 13F filing for Q3 2021, filed 15 Nov 2021.